See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report on:RXII
Edison Investment Research – Pharmaceutical & Healthcare – RXi Pharmaceuticals: RXi Pharmaceuticals (RXi) continues to make solid progress with its development pipeline. We anticipate one of two promising cosmeceutical candidates to enter human testing this year, moving forward on an expedited pathway for potential launch in 2019. We also expect data in H216 in all lead projects including RXI-109 in dermal scarring and in retinal scarring in wet AMD, and Samcyprone in cutaneous warts.
MARLBOROUGH, Mass., April 18, 2016 /PRNewswire/ — RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it will present at the Association for Research in Vision and Ophthalmology (ARVO) 2016 annual meeting. This meeting is the largest gathering of eye and vision researchers in the world drawing 11,000 attendees exploring cutting-edge science. This year’s conference will be held May 1-5, 2016 at the Washington State Convention Center in Seattle, Washington.
Logo – http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
On Sunday, May 1, 2016, new data from ongoing research utilizing the Company’s proprietary RNAi platform in the area of therapeutic topical delivery to the eye, will be presented in the 3:15 – 5:00 p.m. PDT poster session: Corneal Wound Repair and Healing. These data may be viewed on Poster 1280 – D0228 entitled, “sd-rxRNA®: Self-Delivering RNAi Compounds Show Potential for Corneal Indications Following Topical Application.”
The poster will be available under the “Investors – Presentations & Posters” section of the Company’s website, www.rxipharma.com approximately 1 hour following the presentation.
About RXi’s Proprietary Self-delivering RNAi (sd-rxRNA®) Platform
Building on the pioneering work of Dr. Craig Mello, Nobel Laureate and RXi’s Scientific Advisory Board Chairman, scientists at RXi developed novel sd-rxRNA compounds where drug-like properties are built into the RNAi compound itself. These proprietary compounds are novel RNAi compounds with enhanced properties for therapeutic use including: efficient spontaneous cellular uptake, stability, reduced potential for immune stimulation, and potent, long-lasting intracellular activity. All cell types tested (primary, neuronal and non-adherent) internalize sd-rxRNA compounds uniformly and efficiently, resulting in potent and long lasting silencing. Efficient cellular uptake is observed both in vitro and in vivo, as well as in tissues including skin, retina, lung, spinal cord and liver.
RXI-109, an sd-rxRNA compound designed to silence connective tissue growth factor (CTGF), which plays a key role in tissue regeneration and repair, is currently being evaluated in clinical trials. A Phase 1/2 clinical study, RXI-109-1501, is underway to evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases. In addition, a Phase 2 clinical trial, RXI-109-1402, is currently evaluating RXI-109 as a treatment to reduce the recurrence of hypertrophic scars following scar revision surgery. Over 100 subjects have been treated with RXI-109 by intradermal injection in all trials to date. Multiple intradermal injections were well tolerated at all dose levels. RXI-109 was shown to cause a dose-dependent silencing of CTGF messenger RNA and protein levels in the treated areas of the skin compared to placebo and preliminary results from Phase 2a studies indicate a clinical effect on scar appearance.
Sources :
BioPortfolio
The Street
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article with exception to FNJN.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.
